StockData
CNS Pharmaceuticals, Inc. logo

CNS Pharmaceuticals, Inc. (CNSP) stock

CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$4.15+0.67 (+19.25%)

Close on Nov 17, 2026Market cap $6.07MP/E –Yield –

CNS Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

CNS Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.11M, down 0.5% year over year. For fiscal 2025 it was $9.77M, up 5.2% from the year before. The highest annual figure on record is $14.10M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.77M+5.2%
FY2024Dec 31, 2024$9.29M-34.1%
FY2023Dec 31, 2023$14.10M+51.6%
FY2022Dec 31, 2022$9.30M-5.2%
FY2021Dec 31, 2021$9.81M+93.7%
FY2020Dec 31, 2020$5.06M+173.0%
FY2019Dec 31, 2019$1.85M+8619.3%
FY2018Dec 31, 2018$21.27K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.20M+2.9%
Q1 FY2026Mar 31, 2026$3.54M+9.3%
Q4 FY2025Dec 31, 2025$3.17M+111.3%
Q3 FY2025Sep 30, 2025$2.20M-48.2%
Q2 FY2025Jun 30, 2025$1.17M+4.5%
Q1 FY2025Mar 31, 2025$3.24M+33.4%
Q4 FY2024Dec 31, 2024$1.50M-64.9%
Q3 FY2024Sep 30, 2024$4.24M+24.5%
Q2 FY2024Jun 30, 2024$1.12M-60.8%
Q1 FY2024Mar 31, 2024$2.43M-31.9%
Q4 FY2023Dec 31, 2023$4.27M+43.3%
Q3 FY2023Sep 30, 2023$3.41M+54.5%
Q2 FY2023Jun 30, 2023$2.85M+28.1%
Q1 FY2023Mar 31, 2023$3.57M+88.9%
Q4 FY2022Dec 31, 2022$2.98M+26.6%
Q3 FY2022Sep 30, 2022$2.21M-14.4%
Q2 FY2022Jun 30, 2022$2.22M-16.6%
Q1 FY2022Mar 31, 2022$1.89M-14.4%
Q4 FY2021Dec 31, 2021$2.36M+23.0%
Q3 FY2021Sep 30, 2021$2.58M+147.3%
Q2 FY2021Jun 30, 2021$2.66M+78.6%
Q1 FY2021Mar 31, 2021$2.21M+260.0%
Q4 FY2020Dec 31, 2020$1.91M+33.1%
Q3 FY2020Sep 30, 2020$1.04M+220.1%
Q2 FY2020Jun 30, 2020$1.49M+3392.4%
Q1 FY2020Mar 31, 2020$613.08K+1169.1%
Q4 FY2019Dec 31, 2019$1.44M–
Q3 FY2019Sep 30, 2019$325.63K+6979.0%
Q2 FY2019Jun 30, 2019$42.73K–
Q1 FY2019Mar 31, 2019$48.31K–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$4.60K–

More CNS Pharmaceuticals figures

See a number that looks wrong?